Thrombin Generation Capacity of Methylene Blue-Treated Plasma Prepared by the Theraflex MB Plasma System.
BACKGROUND: Methylene blue (MB) / light treatment is a well-known procedure for the inactivation of pathogens in fresh frozen plasma (FFP). Aim of the current study was to investigate the thrombin generation (TG) characteristics and quality of MB plasma prepared by the Theraflex MB Plasma System. METHODS: Single donor plasma units (n = 18) were MB/light-treated, with sampling before and after processing. Preparation included leukocyte depletion, addition of MB pill prior to illumination, and depletion of MB and photoproducts by filtration. Different plasma parameters and TG were measured. TG additionally was determined in solvent/detergent plasma (n = 8). RESULTS: MB/light treatment significantly affected factors V, VIII and XI, which were decreased by 9-18%. While the antigen level was not affected, fibrinogen according to Clauss was decreased by 7%, correlating with a 12% prolongation of TT and RT. The total amount of free thrombin generated, given as 'area under the curve' (AUC), was comparable for untreated (93 +/- 18% of normal plasma) and MB/light-treated plasma (95 +/- 20%). Also peak thrombin concentration was not significantly affected by treatment (94 +/- 11% (untreated) vs. 96 +/- 12% (treated)). The 'time to peak' value (TTP) was 105% of normal plasma for untreated FFP and 89% for MB-treated plasma. CONCLUSION: For plasma treated with the Theraflex MB Plasma System no profound influence of MB/ light treatment on the characteristics of thrombin generation was detected. In concordance with data from the literature, coagulation factors V, VIII and XI were decreased due to MB/ light treatment. Decrease was less than 20%.
Gravemann
Ute
U
DRK-Blutspendedienst NSTOB, Institut Springe, Langen, Germany.
Kusch
Manuela
M
Koenig
Herbert
H
Mohr
Harald
H
Mueller
Thomas H
TH
Transfus Apher Sci. 2006 Dec;35(3):223-33
17118709
Biochim Biophys Acta. 1978 Jan 25;532(1):161-70
620051
Cell Mol Life Sci. 1997 Jan;53(1):29-33
9117995
Transfusion. 1994 Aug;34(8):685-9
8073485
Vox Sang. 2008 May;94(4):306-14
18266780
Immunol Invest. 1995 Jan-Feb;24(1-2):73-85
7713607
Thromb Haemost. 2006 Nov;96(5):553-61
17080210
Blood Rev. 2007 May;21(3):131-42
17208341
Transfus Apher Sci. 2007 Dec;37(3):223-31
18006380
J Thromb Haemost. 2007 May;5(5):1084-5; author reply 1085-7
17355574
Vox Sang. 2007 May;92(4):319-26
17456156
Transfus Med. 2001 Feb;11(1):31-6
11328569
Transfusion. 2003 Sep;43(9):1322-9
12919437
Br J Haematol. 1971 Jul;21(1):43-52
5105276
Transfusion. 2003 Sep;43(9):1238-47
12919426
Transfus Med. 2004 Feb;14(1):39-44
15043592
Vox Sang. 2006 Nov;91(4):285-91
17105603
Thromb Res. 1988 Jan 15;49(2):241-51
2966451
Vox Sang. 1992;63(3):178-85
1448962
Transfus Apher Sci. 2005 Aug;33(1):63-9
16029868
Transfus Med. 2006 Aug;16(4):266-75
16879155
Transfusion. 2004 Jun;44(6):886-90
15157256
Transfusion. 2003 May;43(5):568-75
12702176
Br J Haematol. 2007 Oct;139(2):303-9
17897307
Thromb Res. 1990 Oct 1;60(1):19-32
2148988
Eur J Biochem. 1988 Feb 15;172(1):17-25
3278905
Pathophysiol Haemost Thromb. 2002 Sep-Dec;32(5-6):249-53
13679651
Br J Haematol. 2002 Apr;117(1):253-4
11918568
Transfusion. 2008 Jan;48(1):108-17
17900283
Blood Coagul Fibrinolysis. 2004 Jul;15(5):405-11
15205589